| 史 丽,胡婷婷,李 红,张三明,刘智慧,胡利梅,任卫东.贝那鲁肽与利拉鲁肽对2型糖尿病患者长期结局影响的对比研究[J].现代生物医学进展英文版,2021,(24):4782-4785. |
| 贝那鲁肽与利拉鲁肽对2型糖尿病患者长期结局影响的对比研究 |
| Comparative Study on the Long-Term Outcomes of Benarotide and Liraglutide in Patients With Type 2 Diabetes Mellitus |
| Received:June 26, 2021 Revised:July 22, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.24.038 |
| 中文关键词: 2型糖尿病 利拉鲁肽 贝那鲁肽 血糖 下肢血管功能 肾功能 不良事件 |
| 英文关键词: Type 2 diabetes mellitus Liraglutide Benalutide Blood glucose Lower extremity vascular function Renal function Adverse event |
| 基金项目:张家口市科技攻关计划项目（2021040D）；河北省"三三三人才工程"资助项目（A202103006）；国家自然科学基金资助项目（81471385） |
|
| Hits: 751 |
| Download times: 408 |
| 中文摘要: |
| 摘要 目的：对比分析贝那鲁肽与利拉鲁肽对2型糖尿病患者长期结局的影响，为二甲双胍和磺脲类药物治疗后血糖不能达标的患者应用胰高糖素样肽-1（GLP-1） 受体激动剂提供临床依据。方法：选取2018年3月～2019年3月在我院就诊的使用二甲双胍或者二甲双胍联合磺脲类药物血糖未达标的2型糖尿病患者150例作为研究对象，随机分为观察组和对照组，每组各75例。观察组使用贝那鲁肽注射液治疗，对照组使用利拉鲁肽注射液治疗，所有患者均连续治疗24周。比较两组患者治疗前后空腹血糖（FPG）、餐后2 h血糖（2hPG）、糖化血红蛋白（HbA1c）、收缩期血管峰值血流( PSV)、血管内膜中层厚度(IMT) 、肌酐（Scr）和尿素氮（BUN）水平，两年内的不良事件发生率、心血管相关死亡率和全因死亡率。结果：两组患者之间治疗前、后FPG、2hPG、HbA1c、PSV、IMT、Scr和BUN水平无统计学差异（P>0.05）, 观察组的不良事件总发生率（8.00%）较对照组（20.00%）明显降低（P<0.05），两组患者心血管相关死亡率和全因死亡率相比，差异无统计学意义（P>0.05）。结论：在使用二甲双胍或者二甲双胍联合磺脲类药物血糖未达标的2型糖尿病患者中，与利拉鲁肽相比，贝那鲁肽在降低血糖、改善下肢血管功能、肾功能和死亡率方面无明显差异，但不良事件发生率更低。 |
| 英文摘要: |
| ABSTRACT Objective: To compare the effects of benarotide and liraglutide on the long-term outcome of patients with type 2 diabetes mellitus, and to provide clinical evidence for glucagon like peptide -1 (GLP-1) receptor agonists in patients with hypoglycemia after metformin and sulfonylureas. Methods: 150 patients with type 2 diabetes mellitus who were treated with metformin or metformin combined with sulfonylurea were selected from March 2018 to March 2019, they were randomly divided into the observation group and the control group, 75 cases in each group. The observation group was treated with benarotide injection and the control group was treated with liraglutide injection. All patients were treated for 24 weeks. The levels of fasting blood glucose(FPG), 2 h postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), peak systolic blood flow (PSV), intima-media thickness (IMT), creatinine (Scr) and urea nitrogen (BUN) were compared between the two groups before and after treatment, as well as the incidence of adverse events, cardiovascular related mortality and all-cause mortality within two years. Results: There was no significant difference in the levels of FPG, 2hPG, HbA1c, PSV, IMT, Scr and BUN between the two groups before and after treatment(P>0.05). The total incidence of adverse events in the observation group (8.00%) was significantly lower than that in the control group (20.00%) (P<0.05). There was no significant difference in cardiovascular related death rate and all-cause mortality between the two groups (P>0.05). Conclusion: In type 2 diabetic patients with metformin or metformin combined with sulfonylureas, benarotide has no significant difference in lowering blood sugar, improving blood vessel function, renal function and mortality, but has a lower incidence of adverse events. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
